news for G3 partial responder

[murariji]

Keen to know if there is anything on the market yet for G3's that excludes interferon. Or if not on the market, how far down the pipeline things are. I've heard there have been promising trials. Also an idea of the price would be helpful

[Dee1956]

This is really good news for Geno 3's

Hector we are all praying for you thinking of you

Dee

[murariji]

Thanks Hector.
Sorry to see you're battling with a tumor.
Good luck and all the best,
Murari

[HectorSF]

Next year Gilead's treatment (sofosbuvir + ribavirin) for genotypes 2/3 is expected to be on the market in the US and later in Europe.
-----------------------------------------------------------------------------------------
On April 8, Gilead submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sofosbuvir for the treatment of HCV infection. The data submitted in the NDA support the use of sofosbuvir and RBV as an all-oral therapy for patients with genotype 2 and 3 HCV infection. The Food and Drug Administration has set a target review date of Dec. 8.

Gilead plans to file for regulatory approval of sofosbuvir in other geographies, including the European Union, in the second quarter of 2013. The European Medicines Agency (EMA) has accepted Gilead’s request for accelerated assessment for sofosbuvir, a designation that is granted to new medicines of major public health interest. Accelerated assessment could shorten the EMA’s review time of sofosbuvir by two months. Granting of accelerated assessment does not guarantee a positive opinion from the CHMP or approval by the European Commission.
----------------------------------------------------------------------------------------
Since the product is not available, no one knows what the price with be.

Hector